Newsroom
Class Action Lawsuit Filed Against Caribou Biosciences, Inc. (CRBU)
By KlickAnalytics Data Insights | December 31, 2024 08:02PM ET
Key Points
- Levi & Korsinsky, Bronstein, Gewirtz & Grossman, and Pomerantz Law Firm notify shareholders of a class action lawsuit against Caribou Biosciences, Inc. (CRBU).
- The lawsuit alleges violations of federal securities laws by the company and certain officers.
- Investors who suffered losses between July 14, 2023, and July 16, 2024, are encouraged to join the class action.
- The class action lawsuit aims to recover damages on behalf of affected shareholders.
- The deadline to join the lawsuit is February 24, 2025.
Levi & Korsinsky, Bronstein, Gewirtz & Grossman, and Pomerantz Law Firm have alerted shareholders of Caribou Biosciences, Inc. (CRBU) about a class action lawsuit filed against the company. The lawsuit, alleging violations of federal securities laws by Caribou and certain officers, aims to recover damages on behalf of all persons and entities who purchased or acquired Caribou securities between July 14, 2023, and July 16, 2024.
Investors who suffered losses on their Caribou Biosciences, Inc. investment within the specified dates are encouraged to join the class action lawsuit. The lawsuit, filed in the United States District Court for the Northern District of California, seeks to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 against the company and some of its top officials.
The deadline for investors to join the class action lawsuit is February 24, 2025. Shareholders who wish to learn more about the potential recovery under federal securities laws can visit the provided link or contact Joseph E. Levi, Esq. The lawsuit aims to address damages caused by alleged violations of federal securities laws by Caribou Biosciences, Inc. and certain officers during the specified Class Period.
Overall, shareholders who suffered losses on their Caribou Biosciences, Inc. investment have an opportunity to participate in the class action lawsuit and seek remedies under federal securities laws. It is crucial for affected investors to take action before the upcoming deadline to potentially recover their losses.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with